- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nautilus Biotechnology Inc (NAUT)
Nautilus Biotechnology Inc stock price live, this page displays NASDAQ NAUT stock exchange data. View the NAUT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nautilus Biotechnology Inc real time stock price chart below.
What Is the Nautilus Biotechnology Inc Stock Price Today?
The Nautilus Biotechnology Inc stock price today is 2.470.
What Is the Stock Symbol for Nautilus Biotechnology Inc?
The stock symbol for Nautilus Biotechnology Inc is "NAUT."
What Stock Exchange Does Nautilus Biotechnology Inc Trade On?
Nautilus Biotechnology Inc is listed and trades on the NASDAQ stock exchange.
Is Nautilus Biotechnology Inc a Good Stock to Buy?
Determining whether Nautilus Biotechnology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAUT quote. (ISIN: US63909J1088)
What Is the Nautilus Biotechnology Inc Stock Price Today?
The Nautilus Biotechnology Inc stock price today is 2.470.
What Is the Stock Symbol for Nautilus Biotechnology Inc?
The stock symbol for Nautilus Biotechnology Inc is "NAUT."
What Stock Exchange Does Nautilus Biotechnology Inc Trade On?
Nautilus Biotechnology Inc is listed and trades on the NASDAQ stock exchange.
Is Nautilus Biotechnology Inc a Good Stock to Buy?
Determining whether Nautilus Biotechnology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAUT quote. (ISIN: US63909J1088)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.363
2.570
52 wk Range
0.620
3.080
NAUT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.3632.570
52 wk Range
0.6203.080
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NAUT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
4.000
Upside
+61.94%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Nautilus Biotechnology Inc Company Profile
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology Inc Earnings Call Summary for Q4/2025
- Nautilus cut Q4 2025 operating expenses 23% YoY to $15.4M; FY2025 opex fell 18% to $66.8M with cash burn improving 13.2% to $50.2M.
- Company maintains $156.1M in cash with runway through 2027; stock rose 3.81% in pre-market trading to $3 per share.
- Unveiled Voyager proteomics instrument receiving positive feedback; preparing for commercialization with early access program conversions.
- Projects 15-20% opex increase in 2026 with $65-70M cash burn; expects ~$500K revenue from conversions and grants in 2026.
- Primary revenue ramp anticipated in 2027 with instrument shipments; faces execution risks in development-to-commercialization transition.
Last Updated: 2026-02-26, 09:22 a/m
Read Full TranscriptCompare NAUT to Peers and Sector
Metrics to compare | NAUT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNAUTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.3x | −1.8x | −0.5x | |
PEG Ratio | −0.31 | −0.07 | 0.00 | |
Price/Book | 2.0x | 0.8x | 2.6x | |
Price / LTM Sales | - | 4.1x | 3.2x | |
Upside (Analyst Target) | 61.9% | 44.9% | 51.1% | |
Fair Value Upside | Unlock | 25.7% | 7.3% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4.000
(+61.94% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
-0.11 / -0.14
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Nautilus Biotechnology (NAUT) Stock Price Today?
The Nautilus Biotechnology stock price today is 2.470 USD.
What Stock Exchange Does Nautilus Biotechnology Trade On?
Nautilus Biotechnology is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Nautilus Biotechnology?
The stock symbol for Nautilus Biotechnology is "NAUT."
What Is the Nautilus Biotechnology Market Cap?
As of today, Nautilus Biotechnology market cap is 312.610M USD.
What Is Nautilus Biotechnology's Earnings Per Share (TTM)?
The Nautilus Biotechnology EPS (TTM) is -0.467.
When Is the Next Nautilus Biotechnology Earnings Date?
Nautilus Biotechnology will release its next earnings report on May 05, 2026.
From a Technical Analysis Perspective, Is NAUT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Nautilus Biotechnology Stock Split?
Nautilus Biotechnology has split 0 times.
How Many Employees Does Nautilus Biotechnology Have?
Nautilus Biotechnology has 130 employees.
What is the current trading status of Nautilus Biotechnology (NAUT)?
As of Mar 08, 2026, Nautilus Biotechnology (NAUT) is trading at a price of 2.470 USD, with a previous close of 2.440 USD. The stock has fluctuated within a day range of 2.363 USD to 2.570 USD, while its 52-week range spans from 0.620 USD to 3.080 USD.
What Is Nautilus Biotechnology (NAUT) Price Target According to Analysts?
The average 12-month price target for Nautilus Biotechnology is 4.000 USD, with a high estimate of 4 USD and a low estimate of 4 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +61.94% Upside potential.
What Is the NAUT Premarket Price?
NAUT's last pre-market stock price is 2.600 USD. The pre-market share volume is 1,660.000, and the stock has decreased by 0.160, or 6.560%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.